Live Analyst Rating Changes 16810 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Thomas Wakim
BP

Thomas Wakim

Bell Potter
Wall Street Analyst
★★★☆☆
#1244
on 13Foresight · ranked by our own returns
40%
Success Rate
-7.4%
Average Return
8 of 20 calls profitable · -12.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 40% of Thomas Wakim's ratings turned a profit when each position was held for 1 year — averaging -7.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 11 Hold 0 Sell
Thomas's Stock Coverage 13 ratings · 2026-08-02
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:CSL
CSL
 Jul 31, 2026 HOLD Strong Buy
+54.5% avg upside
16 analysts
$120.00
2.46% Downside
 · ·
AU:PYC
PYC Therapeutics Limited
 Jul 30, 2026 BUY Strong Buy
+101.9% avg upside
3 analysts
$2.30
35.20% Upside
 · ·
AU:SNT
Syntara Limited
 Jul 28, 2026 BUY Strong Buy
+272.5% avg upside
2 analysts
$0.06
135.22% Upside
 +0.0% ·
AU:ALC
Alcidion Group Limited
 Jul 24, 2026 BUY Strong Buy
+53.3% avg upside
2 analysts
$0.15
70.41% Upside
 +3.5% ·
AU:MAP
Microba Life Sciences Limited
 Jul 16, 2026 HOLD Hold
+4.1% avg upside
2 analysts
$0.05
4.08% Upside
 +9.1% ·
AU:CGS
Cogstate Ltd
 Jul 08, 2026 BUY Strong Buy
+47.9% avg upside
1 analyst
$3.70
47.90% Upside
 -12.5% ·
AU:NEU
Neuren Pharmaceuticals Limited
 Jun 29, 2026 BUY Strong Buy
+36.0% avg upside
4 analysts
$23.50
30.58% Upside
 -1.5% ·
AU:CUV
Clinuvel Pharmaceuticals
May 24, 2026 BUY Strong Buy
+233.5% avg upside
3 analysts
$17.00
87.54% Upside
 +4.7% ·
AU:GSS
Genetic Signatures Ltd.
 Apr 07, 2026 HOLD Hold
+69.6% avg upside
1 analyst
$0.10
69.57% Upside
 -27.5% ·
AU:IMM
Immutep Ltd
 Mar 16, 2026 HOLD Hold
+1291.3% avg upside
4 analysts
$0.07
52.09% Upside
 -9.8% ·
AU:ATX
Amplia Therapeutics
 Aug 07, 2025 BUY Strong Buy
+223.0% avg upside
1 analyst
$0.42
222.98% Upside
 -39.0% ·
AU:AHE
MedAdvisor Limited
 May 13, 2025 HOLD Hold
+455.5% avg upside
1 analyst
$0.10
455.54% Upside
 -80.0% ·
AU:CYV
Opthea
Apr 01, 2025 SELL Strong Sell
+113623.8% avg upside
4 analysts
$0.05
316.64% Upside
 · ·
🔒 8 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Thomas Wakim — Frequently Asked Questions
How accurate are Thomas Wakim's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Thomas's ratings were profitable over a one-year hold, with an average return of -7.4% per rating, or +43.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Thomas ranked on 13Foresight?
Thomas Wakim is currently ranked #1244 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Thomas cover?
Thomas most recently has ratings on AU:CSL, AU:PYC, AU:SNT, AU:ALC, AU:MAP, AU:CGS, AU:NEU, AU:CUV, AU:GSS, AU:IMM, AU:ATX, AU:AHE and 1 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.